# A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive

> **NCT06433921** · PHASE1 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 84 (estimated)

## Conditions studied

- Asthma
- Mild Asthma

## Interventions

- **DRUG:** Salbutamol HFA-152a
- **DRUG:** Salbutamol HFA-134a
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06433921
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-14
- **Primary completion:** 2026-10-30
- **Final completion:** 2026-11-06
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2025-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06433921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06433921, "A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT06433921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*